Telling details of breast-cancer recurrence.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Diagnostic accuracy of artificial intelligence-assisted 18f-fdg pet/ct for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.Annals of nuclear medicine · 2026
   Pooled it
2. Paired-Box (PAX) Gene Signatures as a Biomarker of Breast Cancer Progression.International journal of molecular sciences · 2026
   Article
3. Novel L-type chiral metal(II) complexes inhibit breast cancer growth through synergistic effects of anti-angiogenesis, anti-inflammatory, apoptosis induction and cuproptosis.Apoptosis : an international journal on programmed cell death · 2025
   Article
4. Role of RUNX2 in breast cancer development and drug resistance (Review).Oncology letters · 2023
   Review
5. A novel targeted multifunctional nanoplatform for visual chemo-hyperthermia synergy therapy on metastatic lymph nodes via lymphatic delivery.Journal of nanobiotechnology · 2021
   Article
6. Subtype-specific risk models for accurately predicting the prognosis of breast cancer using differentially expressed autophagy-related genes.Aging · 2020
   Article

Corrections and comments

• Comment on
  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.2011
• Comment on
  Status of adjuvant endocrine therapy for breast cancer.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as